Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

BESTCILIA · Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia

FP7Status: CLOSED1 December 201231 May 2016EU funding €2,993,675

Primary Ciliary Dyskinesia (PCD) is a rare genetically heterogeneous disorder which results from dysfunction of motile hair-like organelles (cilia) that results in severe, chronic airways disease. Due to other cilia-related disease mechanisms several other organ systems like the heart can be affected. The complexity of the disease phenotype, late diagnosis, as well as lack of evidence based management guidelines contribute to a high burden of disease and cause high health care costs.Therefore, there is a great need for observational trials as well as well-designed randomised controlled trials to put evidence-based diagnostic and treatment approaches into effect.The main objective of our project is to improve diagnosis and treatment of PCD patients. To accomplish this, we propose to:1) Establish widespread, early diagnosis by introduction of nasal Nitric Oxide measurement as screening tool, and by introduction of high-speed videomicroscopy as diagnostic tool;2) Develop new outcome criteria, especially a PCD-specific quality of life questionnaire, as a prerequisite for controlled PCD trials;3) Establish a PCD registry for both cross-sectional analysis of current disease status and longitudinal observational analysis of disease progression under different regimens;4) Generate evidence-based treatment guidelines by conducting two prospective randomized trials on the inhalation of hypertonic saline and long term azithromycin therapy.To achieve these goals members of the European Respiratory Society’s PCD task force will join forces with members of the NIH-funded US-PCD-network.In our multi-national project, we will for the first time establish evidence-based guidelines for diagnosis, clinical management and therapy. We expect that in a high proportion of children the diagnosis will be established before irreversible lung damage has occurred. In later diagnosed individuals the disease burden will be reduced and chronic respiratory failure retarded.

Consortium · 12 organisations

coordinator

Westfälische Wilhelms-Universität Münster

DE · €563,718

participant

REGION HOVEDSTADEN

DK · €463,951

participant

TECHNOLOGIKO PANEPISTIMIO KYPROU

CY · €259,720

participant

STICHTING VU

NL · €113,053

participant

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

EL · €222,935

participant

EUROPEAN RESEARCH SERVICES GMBH

DE · €100,284

participant

UNIVERSITAET BERN

CH · €393,598

participant

THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

US · €213,793

participant

UNIVERSITY OF SOUTHAMPTON

UK · €193,683

participant

ROYAL BROMPTON AND HAREFIELD NATIONAL HEALTH SERVICE TRUST

UK · €99,820

participant

UNIVERSITY OF MIAMI

US · €108,040

participant

MIEDZYNARODOWY INSTYTUT BIOLOGII MOLEKULARNEJ I KOMORKOWEJ W WARSZAWIE

PL · €261,080

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.